title: Tifluadom (KC 5103) induces suppression and latency changes on somatosensory evoked potentials which are reversed by opioid antagonists.
abstract: Suppression of evoked potentials of the EEG are indicators of analgesia. Tifluadom induces latency changes which are reversed by the kappa-antagonist Mr 2266. Naloxone reverses peak suppression which indicates an additional interaction with the my-opioid-receptor. The specific benzodiazepine antagonist Ro 15-1788 is not effective in reversing peak-changes. Therefore nociceptive stimuli are modulated by tifluadom not only through the interaction with kappa- but also with my-opioid-receptors.
mesh_terms: D000818:Animals; D001569:Benzodiazepines / Q000494:pharmacology*; D002540:Cerebral Cortex / Q000187:drug effects / Q000502:physiology*; D004285:Dogs; D004336:Drug Antagonism; D004558:Electric Stimulation; D005073:Evoked Potentials, Somatosensory / Q000187:drug effects*; D008475:Median Nerve / Q000502:physiology; D009292:Narcotic Antagonists / Q000494:pharmacology*; D011957:Receptors, Opioid / Q000187:drug effects*
chemical_list: D009292:Narcotic Antagonists; D011957:Receptors, Opioid; D001569:Benzodiazepines; C035470:tifluadom